Trial · NCT02611323
Results by group583
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 583
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Participants With CR at EOI Determined by an Independent Review Committee (IRC) on the Basis of Positron Emission Tomography (PET) and Computed Tomography (CT) Scans | FL Dose Escalation: 1.8P+800V+1000G | 100 | 90% Confidence Interval 68.77 to 100.00 | percentage of participants | |
| Percentage of Participants With CR at EOI Determined by an Independent Review Committee (IRC) on the Basis of Positron Emission Tomography (PET) and Computed Tomography (CT) Scans | FL: Dose Expansion: 1.8P+800V+1000G | 51.2 | 90% Confidence Interval 37.44 to 64.86 | percentage of participants | |
| Percentage of Participants With CR at EOI Determined by an Independent Review Committee (IRC) on the Basis of Positron Emission Tomography (PET) and Computed Tomography (CT) Scans | DLBCL Dose Escalation: 1.8P+800V+375R | 25 | 90% Confidence Interval 4.64 to 59.97 | percentage of participants | |
| Percentage of Participants With CR at EOI Determined by an Independent Review Committee (IRC) on the Basis of Positron Emission Tomography (PET) and Computed Tomography (CT) Scans | DLBCL Dose Expansion: 1.8P+800V+375R | 32.5 | 90% Confidence Interval 20.41 to 46.63 | percentage of participants | |
| FL Cohorts: Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) | FL Dose Escalation: 1.4P+400V+1000G | AEs | 100 | percentage of participants | |
| FL Cohorts: Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) | FL Dose Escalation: 1.4P+200V+1000G | AEs | 100 | percentage of participants | |
| FL Cohorts: Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) | FL Dose Escalation: 1.8P+400V+1000G | AEs | 100 | percentage of participants | |
| FL Cohorts: Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) | FL Dose Escalation: 1.4P+600V+1000G | AEs | 100 | percentage of participants | |
| FL Cohorts: Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) | FL Dose Escalation: 1.8P+600V+1000G | AEs | 100 | percentage of participants | |
| FL Cohorts: Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) | FL Dose Escalation: 1.8P+800V+1000G | AEs | 100 | percentage of participants | |
| FL Cohorts: Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) | FL: Dose Expansion: 1.8P+800V+1000G | AEs | 100 | percentage of participants | |
| FL Cohorts: Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) | FL Dose Escalation: 1.4P+400V+1000G | SAEs | 57.1 | percentage of participants | |
| FL Cohorts: Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) | FL Dose Escalation: 1.4P+200V+1000G | SAEs | 33.3 | percentage of participants | |
| FL Cohorts: Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) | FL Dose Escalation: 1.8P+400V+1000G | SAEs | 33.3 | percentage of participants | |
| FL Cohorts: Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) | FL Dose Escalation: 1.4P+600V+1000G | SAEs | 0 | percentage of participants | |
| FL Cohorts: Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) | FL Dose Escalation: 1.8P+600V+1000G | SAEs | 22.2 | percentage of participants | |
| FL Cohorts: Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) | FL Dose Escalation: 1.8P+800V+1000G | SAEs | 75.0 | percentage of participants | |
| FL Cohorts: Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) | FL: Dose Expansion: 1.8P+800V+1000G | SAEs | 34.1 | percentage of participants | |
| DLBCL Cohorts: Percentage of Participants With AEs and SAEs | DLBCL: Dose Escalation: 1.8P+400V+375R | AEs | 100 | percentage of participants | |
| DLBCL Cohorts: Percentage of Participants With AEs and SAEs | DLBCL Dose Escalation: 1.8P+600V+375R | AEs | 100 | percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02611323/results